Our pipeline leverages our proprietary ocular delivery technologies, which are designed to maintain potent and effective drug levels in ocular tissue for up to 12 months and potentially longer, to improve patient compliance, reduce healthcare burdens and ultimately improve clinical outcomes.

Our proprietary ocular delivery technologies are designed to allow sustained delivery of pharmacologic agents to the eye in a well-tolerated and controlled manner to achieve extended duration of effectiveness. The delivery technologies are depot formulations of microparticles containing biodegradable polymers such as poly(lactic-co-glycolic acid), or PLGA. Historically, PLGA-based delivery systems have resulted in inflammation of the eye, limiting their applicability in ophthalmology. Our microparticles are engineered to carry a polyethylene glycol, or PEG, coating that helps eliminate or minimize inflammation typically associated with intraocular administration of conventional PLGA microparticles.

We demonstrated in animal studies and in our Phase 1/2a clinical trial that our microparticles are well-tolerated in the eye. Furthermore, our microparticles are designed to aggregate after IVT injection upon exposure to the vitreous fluid at body temperature to form a depot at the bottom of the eye, outside of the visual axis. The microparticles then gradually release the active ingredient at a variable rate depending on the exact composition of the polymer and biodegrade into lactic acid, glycolic acid and PEG that are naturally cleared from the body. Our research and development team has developed our product pipeline with different pharmacologic agents using these technologies.

Graybug Vision was founded in September 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine.

Graybug Vision’s initial technology was co-developed by founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with co-founders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute, Peter A. Campochiaro, MD and Peter J. McDonnell, MD.